Andrea Carfi, Ph.D., is the head of research for infectious disease at Moderna, leading all research efforts for infectious disease targets. The infectious disease division focuses on discovery and development of vaccines as well as therapeutic and prophylactic approaches against infectious disease targets using Moderna proprietary mRNA technology.
Carfi has more than 15 years of experience in drug discovery and vaccine development at Moderna, GSK, Novartis Vaccines and IRBM/Merck. Over the years he has held roles of increasing responsibility with a focus on structural biology, antigen design, small molecule antivirals discovery and vaccines development. Carfi joined Moderna in 2017 as head of antigen design and selection and project leader for the CMV vaccine program now in a phase one clinical trial.
Prior to Moderna Carfi worked at GSK and Novartis Vaccines for seven years. During this time he led the U.S. based Protein Biochemistry team which was responsible for the design, selection, characterization and early development of novel vaccine targets against viral infectious disease. Some of these vaccine candidates are now in early and late stage clinical trials. Carfi also led the Novartis Vaccines Antigen Design platform across the research sites of Cambridge, Mass., (U.S.) and Siena, Italy.
Carfi holds a master of science in physics from University of Canterbury (U.K.), master of science in chemistry from Pavia University (Italy), and a Ph.D. in biophysics from Université Joseph Fourier (France). He also trained as a postdoctoral fellow in the laboratories of Stephen Harrison and Don Wiley at Boston Children’s Hospital (Mass., U.S.).